Despite decreases in endophilin and clathrin protein levels in the presence of LRRK2 mutations in our in vitro and in vivo models, increases in both of these proteins were seen in post-mortem tissue from PD patients carrying the LRRK2-G2019S mutation compared with controls. This evidence concerns the gene LRRK2 and Parkinson disease.